A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer

Kelly, William Kevin ; Thanigaimani, Pradeep ; Sun, Furong ; Seebach, Frank A. ; Lowy, Israel ; Sandigursky, Sabina ; Miller, Elizabeth

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS5105-TPS5105 [Periódico revisado por pares]

Texto completo disponível